1. Scrip
  2. >>Focus On Asia
  3. >>Japan

Leqembi Set For Japan Launch After Twisty Pricing Process

Close Monitoring Under Conditional Approval

 
• By Lisa Takagi

Eisai/Biogen's Alzheimer's drug will be launched in Japan on 20 December with a lower price premium than Eisai was negotiating for after back-and-forth reimbursement negotiations, and strict use and monitoring restrictions.

Eisai has faced tough pricing negotiation with the MHLW for lecanemab, although both sides recognize its value.
Eisai faced tough Japan price negotiations for Leqembi, but both sides recognized value • Source: Shutterstock

Japan’s Ministry of Health, Labour and Welfare (MHLW) has set the initial reimbursement price for Eisai Co., Ltd./Biogen, Inc.’s Alzheimer's drug Leqembi (lecanemab) under the national health insurance (NHI) scheme, paving the way for a market launch in the country on 20 December. 

The intravenously administered, amyloid beta-targeting antibody, approved for slowing the progression of mild cognitive impairment and mild dementia due to...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Japan

Industry Excellence Celebrated At Citeline Japan Awards

 
• By Ian Haydock

Excellence, innovation and deal-making across the Japanese biopharma sector were celebrated at the Citeline Japan Awards 2025, held in Tokyo on 21 October.

Viatris Looks To Expand Japan Presence With Aculys Acquisition

 
• By Lisa Takagi

Global generics-focused giant acquires Japanese venture with late-stage, two-asset CNS pipeline as it looks to build presence in Japan.

Zolbetuximab Loses GLEAM In Pancreatic Cancer

 
• By Lisa Takagi

Astellas's first-in-class CLDN18.2-targeting antibody has missed its primary endpoint in a Phase II trial for pancreatic cancer and is facing increasingly fierce same-class competition in this and other indications.

Sakaguchi’s Nobel Brings Cheer To Japan Biopharma

 
• By Lisa Takagi

Japan's latest Nobel Prize win sparks hopes for renewed investment in biopharma R&D by the national government, including in a venture co-founded by the winner.

More from Focus On Asia

ESMO 25: Akeso’s Ivonescimab Triumphs In 1L Squamous NSCLC, With Longest PFS In China Population

 
• By Dexter Jie Yan

Besting BeOne Medicines’ Tevimbra plus chemotherapy, interim results from the head-to-head HARMONi-6 study of Akeso's ivonescimab plus chemotherapy show the combo might have the longest PFS versus its single-target immuno-oncology competitors.

Asia Deal Watch: Chugai Teams With Rani On Oral Version Of Rare Disease Antibody Drug

 
• By Joseph Haas, Jung Won Shin, Lisa Takagi, Xu Hu, and Vibha Ravi

Plus deals involving Astellas/Taysha, Haihe/Taiho, AimedBio/Boehringer Ingelheim, Takeda/Nabla, CytoMed/TC BioPharm, Specialised Therapeutics/CanariaBio, UgeneX/AviadoBio, Lupin, Kissei/Searchlight, Kazia/QIMR and Prism/Servier.

Hansoh/Roche ADC Deal Caps Chinese One-Day Licensing Spree

 
• By Dexter Jie Yan

Multiple Chinese biopharma firms reach new deals with major Western and other partners in a spree of licensing deals over a one-day period, with ADCs, in vivo CAR and bifunctional fusion protein therapies among the target assets.